News & Events
Press Releases
View our latest company updates.
- Tessellate Bio Appoints Katie Chapman as Chief Scientific Officer 01 October 2025
- Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers 23 April 2025
- Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer 04 November 2024
- Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers 30 September 2024
- Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board 01 May 2024
- Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board 15 November 2023
- Tessellate BIO Emerges from Stealth 17 October 2023
Events
There are currently no upcoming events
In the news
Tessellate Bio and Boehringer Ingelheim win 2025 European Lifestars Award in the category Deal of the Year (>€500M)
17 November 2025
European Lifestars Awards
View Post [LinkedIn]
Tessellate: Identifying new synthetic lethality pairs
5 August 2025
BioCentury
View Story [Behind a paywall]
CEO Interview
30 May 2025
MSA Partners US Pharmaceutical Industry Newsletter
View Story (PDF – Japanese)
CEO Interview
20 May 2025
BiotechTV
Watch video
Tessellate Bio at AACR
16 May 2025
Base to Base Biotech Interview
Listen to the podcast
CEO Spotlight
24 April 2025
Stevenage Bioscience Catalyst
Watch video
Boehringer taps Dutch biotech for ALT positive cancer pact exceeding $573M in biobucks
23 April 2025
Endpoints News
View Story
Boehringer inks Tessellate deal to slot synthetic lethal program into oncology pipeline
23 April 2025
Fierce Biotech
View Story
Boehringer Ingelheim and Tessellate Bio tackle hard-to-treat cancers in €500m deal
23 April 2025
Business Weekly
View Story
The Netherlands: Boehringer Ingelheim gains exposure to ALTs through Tessellate Bio partnership
23 April 2025
Investors in Healthcare
View Story
Tessellate Bio has appointed Dr Lara Boyd as Chief Business Officer
Pharma Times
25 November 2024
View Story
Tessellate Bio in historic cancer research initiative
30 September 2024
Business Weekly
View Story
Tessellate Bio, CMRI and Omico collaborate to target ALT-positive cancers
30 September 2024
BioWorld
View Story [Behind a paywall]
The Promise of Synthetic Lethality in Precision Oncology
1 September 2024
Drug Discovery World
Download article
Tessellate Bio draws $8.4M in seed to try alternative synthetic lethality approach
8 December 2023
BioWorld
View story [Behind a paywall]
Emerging From Stealth Mode, Tessellate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs
17 October 2023
Scrip
View story [Behind a paywall]
The Netherlands: Tessellate BIO emerges from stealth
17 October 2023
Investors in Healthcare
View story [Behind a paywall]
The Promise of Synthetic Lethality in Precision Oncology
1 September 2024
Drug Discovery World
Download article
Tessellate Bio draws $8.4M in seed to try alternative synthetic lethality approach
8 December 2023
BioWorld
View story [Behind a paywall]
Emerging From Stealth Mode, Tesselate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs
17 October 2023
Scrip
View story [Behind a paywall]
The Netherlands: Tessellate BIO emerges from stealth
17 October 2023
Investors in Healthcare
View story [Behind a paywall]
© Tessellate Bio
